Also trades as: SUVENPHAR.NS (NSE) · $vol 3M

₹1,075.30

Last traded 2025-06-10 — delisted

BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ₹411.4B mcap · 152M float · 0.0048% daily turnover

Revenue

$12.0B +13.9% ▲

5Y CAGR: +8.2%

Gross Profit

$8.2B +20.9% ▲

5Y CAGR: +11.2%

Operating Income

$5.7B +4.7% ▲

5Y CAGR: +9.6%

Net Income

$2.7B -10.8% ▼

5Y CAGR: -3.3%

EPS (Diluted)

$10.45 -11.4% ▼

5Y CAGR: -3.4%

EBITDA

$4.1B -0.8% ▼

5Y CAGR: +0.3%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$9.8B	$12.9B	$13.4B	$10.5B	$12.0B
YoY Growth	+21.4%	+31.6%	+3.9%	-21.6%	+13.9%
Cost of Revenue	$4.2B	$5.6B	$5.9B	$4.5B	$3.8B
Gross Profit	$5.6B	$7.3B	$7.5B	$6.0B	$8.2B
Gross Margin	57.1%	57.0%	56.3%	57.3%	68.6%
R&D Expenses	$111M	$104M	$86M	$0	$0
SG&A Expenses	$266M	$369M	$366M	$1.4B	$2.6B
Operating Expenses	$1.5B	$1.9B	$2.4B	$1.4B	$2.6B
Operating Income	$4.1B	$5.4B	$5.2B	$4.6B	$5.7B
Operating Margin	41.8%	42.0%	38.7%	43.8%	47.2%
Interest Expense	$114M	$84M	$128M	$75M	$124M
Income Before Tax	$4.7B	$6.7B	$5.6B	$4.1B	$3.4B
Tax Expense	$1.1B	$2.1B	$1.5B	$1.1B	$792M
Net Income	$3.6B	$4.5B	$4.1B	$3.0B	$2.7B
Net Margin	37.0%	35.2%	30.7%	28.6%	22.4%
EPS (Diluted)	$14.23	$17.83	$16.16	$11.80	$10.45
EBITDA	$4.6B	$6.7B	$6.2B	$4.7B	$4.1B
Shares Outstanding	255M	255M	255M	255M	256M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$2.2B	$2.5B	$2.3B	$2.6B	$3.1B	$4.0B	$5.5B	$5.6B
Cost of Revenue	$1.1B	$1.8B	$1.5B	$521M	$556M	$2.0B	$1.5B	$1.4B
Gross Profit	$1.1B	$760M	$810M	$2.1B	$2.5B	$2.0B	$4.0B	$4.1B
Gross Margin	52.2%	30.1%	35.1%	79.8%	81.9%	49.1%	73.0%	74.6%
R&D Expenses	$23M	$23M	$0	$0	$0	$0	$0	$0
SG&A Expenses	$144M	$199M	$456M	$498M	$633M	$957M	$1.3B	$0
Operating Expenses	$623M	$199M	$456M	$2.1B	$633M	$957M	$1.3B	$3.4B
Operating Income	$667M	$561M	$944M	$870M	$1.9B	$1.0B	$2.7B	$769M
Operating Margin	30.4%	22.2%	40.9%	33.8%	61.3%	25.3%	48.8%	13.8%
Interest Expense	$13M	$25M	$16M	$17M	$33M	$58M	$0	$88M
Income Before Tax	$655M	$709M	$831M	$995M	$1.1B	$516M	$628M	$838M
Tax Expense	$187M	$175M	$223M	$175M	$264M	$129M	$164M	$174M
Net Income	$468M	$534M	$608M	$820M	$829M	$420M	$489M	$741M
Net Margin	21.3%	21.1%	26.3%	31.8%	27.0%	10.4%	8.9%	13.3%
EPS (Diluted)	$1.84	$2.10	$2.39	$3.21	$3.23	$1.57	$1.27	$2.90
EBITDA	$795M	$904M	$799M	$1.2B	$1.1B	$965M	$862M	$1.4B
Shares Outstanding	255M	255M	254M	255M	257M	264M	385M	256M

SUVENPHAR.BO BSE